← Back to all trials
Not Yet Recruiting
NCT07850336
Pancreatic Endoscopic Ultrasound-guided RadioFrequency for Inoperable Carcinoma Treatment
Conditions: Pancreatic Ductal Adenocarcinoma (PDAC)
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: NA
Enrollment: 56
Sponsor: Bojan Kovacevic
Summary
The purpose of this study is to evaluate whether endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) affects survival in patients with inoperable pancreatic carcinoma. By using a prospective single-arm design with historical controls, this study aims to generate clinically relevant data while minimizing the number of patients exposed to experimental treatment. The findings may support future integration of EUS-RFA into standard care for this high-need patient population.
Eligibility Criteria
Inclusion Criteria:
* Adult habile patients with a signed informed consent
* Histologically confirmed pancreatic carcinoma ≤5 cm in largest diameter
* ECOG performance status 0-2
* Patients not eligible for curative-intended surgical treatment due to:
Advanced (unresectable) disease, or Unsuitability for surgery due to comorbidities or poor performance status, or Patient preference to decline surgery
Exclusion Criteria:
* Metastatic disease
* Uncorrected coagulopathy (INR ≥1.5 or thrombocyte count \< 50 mia/L)
* Altered anatomy or interposition of major vessels precluding safe EUS-RFA
* Active untreated infection or pancreatitis
* Life expectancy \
Source: ClinicalTrials.gov (NCT07850336). StuddyBuddy aggregates publicly available trial information.